Avammune Therapeutics Secures $12 Million for Cancer Therapy Advancements

Fast Summary

• Bengaluru and Philadelphia-based biopharmaceutical startup Avammune Therapeutics has raised $12 million (Rs 100 crore) in a Series A funding round.
• Investors include Capital 2B, Shastra VC, Kotak Lifesciences Fund I, IvyCap Ventures, and returning investor 1Crowd.
• Founded in 2020 by Arun Papaiah, Srinivasan namala, and Aditya Kulkarni, the company focuses on developing small molecule immunotherapies that activate the body’s innate immune system to treat cancers and autoimmune disorders.
• The funding will support clinical trials for its lead asset AVA-NP-695, an ENPP1 inhibitor showing promise against osteosarcoma, Ewing’s sarcoma, and triple-negative breast cancer. Early tests have been conducted through compassionate-use programs.
• CEO Arun Papaiah notes this approach could make therapies more accessible compared to biologic drugs requiring injections.
• Immuno-oncology (IO) therapies target the immune system to combat cancer but face limitations; only 30-40% of patients respond to existing treatments like checkpoint inhibitors.
• The global IO market is valued at $100 billion with a projected growth rate of 17% CAGR.
• Avammune’s pipeline includes preclinical assets such as AVA-ADR (an ADAR1 p150 inhibitor) and a proprietary chemical library targeting DNA/RNA-binding proteins for precise treatment protocols at lower doses.
• Collaborations include partnerships with institutions like UCSF, Oxford University, and University of Queensland.

Indian Opinion Analysis

Avammune Therapeutics’ innovative focus on activating innate immunity offers significant potential for India amid rising demand for affordable cancer treatments. Existing IO therapies are often prohibitively expensive biologic solutions less accessible in emerging markets like India-a challenge Avammune seeks to address with small molecule immunotherapies that may be more cost-effective.

The funding also highlights growing investment interest in biotech innovations from Indian venture capital firms such as Kotak Lifesciences Fund I-a promising sign for India’s healthcare ecosystem. If triumphant in human trials planned ahead for AVA-NP-695 therapy-particularly its applications against hard-to-treat cancers-the implications could range from improved patient outcomes to enhanced domestic research capabilities within oncology.

Moreover, collaborations with renowned global institutions position Avammune well strategically while advancing India’s contributions toward cutting-edge drug discovery worldwide.

Read More